Stockreport

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics, Inc.  (COYA) 
PDF Company underscores potential benefits of low-dose interleukin-2 in Investigator-Initiated Phase 2 Alzheimer’s disease trial as presented at the recent CTAD Conference [Read more]